Healthy Volunteer Clinical Trial
Official title:
Effects of Interrupting Sedentary Behavior on Metabolic and Cognitive Outcomes in Children
| Verified date | January 29, 2018 |
| Source | National Institutes of Health Clinical Center (CC) |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Background:
- Some studies in adults have found that insulin and glucose blood levels are lower when a
long period of sitting is broken up with walking, compared to sitting without breaks. This
means that the body can better process sugars when there are walking breaks during the day.
Researchers want to know if this is also true for children. Some studies have found that
children s attention and memory might be better after exercise. Researchers want to know if
short walking breaks have the same effects.
Objectives:
- To understand if breaking up sitting with walking helps children s bodies better use sugars
and improves children s concentration.
Eligibility:
- Healthy children ages 7 to 11.
Design:
- Participants will be screened with a physical exam, medical history, exercise test,
picture vocabulary test, and medical tests including blood tests and X-rays.
- Participants will return for two 7-hour visits. In the month before the visits, they
will wear a physical activity monitor for one week so researchers know how active they
are. Once they will take the sitting only test and once the sitting breaks test.
- During the sitting only test, participants will sit for 3 hours.
- During the sitting breaks test, they will sit for 3 hours with 3-minute walking breaks
every 30 minutes.
- Both days, they will drink sugar water. Then the participants will have blood drawn from
a needle that is kept in place, and they will wear a heart monitor. They will take
attention and working memory tests on a computer and answer questions about how they
feel. They will eat a meal at the end of the test day.
| Status | Completed |
| Enrollment | 89 |
| Est. completion date | January 29, 2018 |
| Est. primary completion date | March 8, 2017 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 7 Years to 11 Years |
| Eligibility |
- INCLUSION CRITERIA: Participants will qualify for the study if they meet the following criteria: 1. Good general health. 2. Age greater than or equal to 7 and <11.99 years. 3. Fasting plasma glucose < 100 mg/dL 4. a) Phase 1: Body mass index (BMI) between the 5th and 85th percentiles, as determined by the CDC age- and sex- specific growth charts. b) Phase 2: BMI above the 85th percentile, as determined by the CDC age- and sex- specific growth charts. EXCLUSION CRITERIA: 1. Significant cardiac or pulmonary disease likely to or resulting in hypoxia or decreased perfusion. 2. Evidence of impaired glucose tolerance or type 2 diabetes, including fasting plasma glucose greater than or equal to 100 mg/dL. 3. Presence of other endocrinologic disorders leading to obesity (e.g.: Cushing Syndrome). 4. Participants who have, or whose parent/guardians have, current substance abuse or a psychiatric disorder or other condition that, in the opinion of the investigators, would impede competence, compliance, or prevent the completion of the study. 5. Participants who have, or are currently receiving, anti-psychotic drugs that would affect metabolism, cognitive outcomes, and body habitus. 6. Participants receiving medical treatment other than diet for hypertension or dyslipidemia. 7. Participants with precocious puberty and/or receiving androgen and estrogen therapy. 8. Participants currently taking medications for ADHD, or any disorder or use of medications known to affect body composition or weight. 9. Presence of pre-existing neurocognitive disabilities, or an age-adjusted score below 85 on the Picture Vocabulary Test at the screening visit. |
| Country | Name | City | State |
|---|---|---|---|
| United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
| Lead Sponsor | Collaborator |
|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | National Cancer Institute (NCI), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Jago R, Harrell JS, McMurray RG, Edelstein S, El Ghormli L, Bassin S. Prevalence of abnormal lipid and blood pressure values among an ethnically diverse population of eighth-grade adolescents and screening implications. Pediatrics. 2006 Jun;117(6):2065-73. — View Citation
Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11. 2002 May;(246):1-190. — View Citation
Ventura E, Davis J, Byrd-Williams C, Alexander K, McClain A, Lane CJ, Spruijt-Metz D, Weigensberg M, Goran M. Reduction in risk factors for type 2 diabetes mellitus in response to a low-sugar, high-fiber dietary intervention in overweight Latino adolescents. Arch Pediatr Adolesc Med. 2009 Apr;163(4):320-7. doi: 10.1001/archpediatrics.2009.11. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Lower insulin incremental area under the curve (iAUC) during 3 hours after the OGTT. | 3 hours | ||
| Secondary | Lower postprandial glucose iAUC during 3 hours after the OGTT. | 3 hours | ||
| Secondary | Differences in executive functioning and attention scores. | 3 hours | ||
| Secondary | Differences in positive and negative affect scores. | 3 hours | ||
| Secondary | Differences in anxiety. | 3 hours | ||
| Secondary | Differences in post-test dietary intake. | 3 hours |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06326723 -
Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT00001367 -
Diagnosis and History Study of Patients With Different Neurological Conditions
|
||
| Completed |
NCT02699710 -
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02231892 -
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
|
N/A | |
| Not yet recruiting |
NCT06441916 -
Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions
|
Phase 1 | |
| Completed |
NCT03771586 -
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
|
Phase 1 | |
| Not yet recruiting |
NCT06337422 -
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
|
Phase 1 | |
| Completed |
NCT03302182 -
Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT05049343 -
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
|
Phase 1 | |
| Recruiting |
NCT01629108 -
Normal Values in Hearing and Balance Testing
|
||
| Completed |
NCT02947854 -
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
|
Phase 1 | |
| Completed |
NCT02534870 -
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
|
Phase 1 | |
| Completed |
NCT02224053 -
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01684891 -
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT01676584 -
A Study of Single Dose RO6811135 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT01697436 -
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
|
Phase 1 | |
| Completed |
NCT01711762 -
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
|
Phase 1 | |
| Completed |
NCT01461967 -
A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT02547259 -
Influence of Emotion in a Test Run Forgetfulness
|
N/A | |
| Completed |
NCT01591850 -
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
|
Phase 1 |